Related references
Note: Only part of the references are listed.Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+breast cancer
X. He et al.
ANNALS OF ONCOLOGY (2012)
Metformin and breast cancer risk: a meta-analysis and critical literature review
Nananda F. Col et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer
Soley Bayraktar et al.
CANCER (2012)
The impact of type 2 diabetes mellitus on cancer-specific survival A Follow-Up Study in Sweden
Xiangdong Liu et al.
CANCER (2012)
Mortality After Incident Cancer in People With and Without Type 2 Diabetes Impact of metformin on survival
Craig J. Currie et al.
DIABETES CARE (2012)
Diabetes, Metformin, and Breast Cancer in Postmenopausal Women
Rowan T. Chlebowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Type 2 diabetes mellitus and prognosis in early stage breast cancer women
Muhammet Ali Kaplan et al.
MEDICAL ONCOLOGY (2012)
Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial
Sirwan Hadad et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth
Yin-Hsun Feng et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2011)
National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants
Goodarz Danaei et al.
LANCET (2011)
Association between Body-Mass Index and Risk of Death in More Than 1 Million Asians
Wei Zheng et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Metformin extends life span of HeR-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo
Vladimir N. Anisimov et al.
CELL CYCLE (2010)
Linking diabetes and cancer: a consensus on complexity
Andrew Renehan et al.
LANCET (2010)
Metabolic syndrome and postmenopausal breast cancer in the ORDET cohort: A nested case-control study
C. Agnoli et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2010)
The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells
Alejandro Vazquez-Martin et al.
CELL CYCLE (2009)
New Users of Metformin Are at Low Risk of Incident Cancer A cohort study among people with type 2 diabetes
Gillian Libby et al.
DIABETES CARE (2009)
Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer
Sao Jiralerspong et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Proliferation markers and survival in early breast cancer: A systematic review and meta-analysis of 85 studies in 32,825 patients
R. Stuart-Harris et al.
BREAST (2008)
The Effects of Adiponectin and Metformin on Prostate and Colon Neoplasia Involve Activation of AMP-Activated Protein Kinase
Mahvash Zakikhani et al.
CANCER PREVENTION RESEARCH (2008)
Long-term All-Cause Mortality in Cancer Patients With Preexisting Diabetes Mellitus A Systematic Review and Meta-analysis
Bethany B. Barone et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole
Giuseppe Viale et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
The Impact of Transgenic IGF-IR Overexpression on Mammary Development and Tumorigenesis
Robert A. Jones et al.
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA (2008)
Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells
Ryan J. O. Dowling et al.
CANCER RESEARCH (2007)
Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients
E. de Azambuja et al.
BRITISH JOURNAL OF CANCER (2007)
Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis
T Lopez et al.
CANCER CELL (2002)
Share Paper
